Eupraxia Pharmaceuticals (EPRX) Liabilities and Shareholders Equity (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $145.4 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 397.22% year-over-year to $145.4 million in Q1 2026; TTM through Mar 2026 was $347.4 million, a 249.14% increase from a year earlier, with the FY2025 full-year figure at $86.2 million, up 146.55% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $145.4 million, up from $86.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for EPRX reached as high as $145.4 million in Q1 2026 and fell as low as $10.4 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $47.5 million across 5 years, with a median of $29.2 million in 2025.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 790.98% in 2025 and fell as far as 20.21% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $19.1 million in 2022, then advanced by 5.98% to $20.3 million in 2023, then soared by 72.42% to $34.9 million in 2024, then jumped by 146.55% to $86.2 million in 2025, then jumped by 68.72% to $145.4 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $145.4 million in Q1 2026, $86.2 million in Q4 2025, and $92.3 million in Q3 2025.